March 2026 in “American Journal of Clinical Dermatology” Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
March 2026 in “Dermatology and Therapy” More severe alopecia areata can lower quality of life.
February 2026 in “International Journal of Homoeopathic Sciences” Individualized homeopathic treatment with Lycopodium clavatum may help manage alopecia areata and improve related emotional symptoms.
January 2026 in “Dermatology Practical & Conceptual” Triamcinolone acetonide is more effective than cryotherapy for hair regrowth in alopecia areata but has different side effects.
January 2026 in “Dermatology and Therapy” Patients with alopecia areata on ritlecitinib responded well to tetanus and meningococcal vaccines.
January 2026 in “BULLETIN OF STOMATOLOGY AND MAXILLOFACIAL SURGERY” Both treatments help hair regrowth, but Botulinum Toxin-A has fewer side effects.
January 2026 in “Frontiers in Medicine” Alopecia areata in Taiwan has a high disease burden and needs better research and diagnostic criteria.
January 2026 in “Dermatology Online Journal” COVID-19 vaccination may be linked to alopecia areata, especially in young adults.
January 2026 in “Clinical Cosmetic and Investigational Dermatology” Stressful life events may trigger alopecia areata.
December 2025 in “Babcock University Medical Journal” CD27 and IL-35 can help diagnose alopecia areata linked to bacterial infections.
December 2025 in “IP Indian Journal of Clinical and Experimental Dermatology” DNCB is more effective than betamethasone for hair regrowth but has more side effects.
December 2025 in “Dermatology The American Medical Journal” JAK inhibitors are effective for long-term management of alopecia areata.
November 2025 in “The Bioscan.” Pix Liquida may help treat alopecia areata.
Higher air pollution increases the risk of alopecia areata.
September 2025 in “Tạp chí Da liễu học Việt Nam” Combining oral methylprednisolone with microneedle radiofrequency improves hair growth in alopecia areata but may cause pain and side effects.
August 2025 in “Libyan Medical Journal” People with vitiligo or alopecia areata have higher anxiety and depression than healthy people.
August 2025 in “Scientific Electronic library online (Sciences Carlos III Health Institute)” Tofacitinib can help regrow hair in about 50% of people with moderate-severe alopecia areata.
July 2025 in “Journal of Dermatology Research Reviews & Reports” A 10-year-old girl with hair and eyelash loss showed significant regrowth after treatment.
July 2025 in “Pakistan Journal of Intensive Care Medicine” Clobetasol propionate 0.05% ointment is more effective than tacrolimus 0.1% ointment for treating alopecia areata.
July 2025 in “Dermatology and Therapy” Patients with fewer past treatments for alopecia areata respond better to baricitinib.
July 2025 in “International Journal of Pharmaceutical Sciences Review and Research” Individualized treatment and psychological support improved the patient's quality of life and appearance despite medication side effects.
April 2025 in “PharmacoEconomics - Open” Patients with Alopecia Areata are willing to trade life duration for better quality of life.
February 2025 in “Revista Eletrônica Acervo Saúde” Triamcinolone hexacetonide is effective but has side effects, while PRP and minoxidil are safer alternatives for treating alopecia areata.
January 2025 in “SKIN The Journal of Cutaneous Medicine” Calcipotriol's effectiveness for treating alopecia areata is unclear and needs more research.
January 2025 in “TURKDERM” Alopecia areata incognito in children can be effectively treated with triamcinolone acetonide and supplements, leading to full hair regrowth.
January 2025 in “International Journal of Homoeopathic Sciences” Personalized homeopathic treatment may help manage alopecia areata.
January 2025 in “International Journal of Dermatology Research” Higher MPV and CRP levels may indicate more severe alopecia areata.
October 2024 in “La Tunisie Médicale” Over half of alopecia areata patients in Tunisia experience depression, highlighting the need for psychological support.
September 2024 in “South Eastern European Journal of Public Health” Alopecia areata patients have higher IgE and IL-13 levels, suggesting immune involvement.
September 2024 in “Archives of Medical Science” Alopecia areata is linked to immune system differences, with specific biomarkers like CXCL9 and CXCL10 being key for diagnosis and potential treatment targets.